Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for CKD-MBD Markers
NCT05601271Completed
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in chronic kidney disease (CKD) comparing Allopurinol with Placebo (2 arms). Primary endpoints: 1,25-dihydroxyvitamin D Concentration at 3 months, Fibroblast Growth Factor 23 at 3 months and 1 more. Started Mar 2021; status: completed.
02
Drugs
allopurinol
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05601271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601271.